Method of treating microbial infections

• US 5,972,933 A
• Filed: 01/08/1998
• Issued: 10/26/1999
• Est. Priority Date: 01/08/1998
• Status: Expired due to Term

• Current Assignee: ED. Geistlich Soehne AG Fuer Chemische Industrie
• Original Assignee: ED. Geistlich Soehne AG Fuer Chemische Industrie
• Inventors: Pfirrmann, Rolf W.
• Primary Examiner(s): Housel, James C.
• Assistant Examiner(s): Devi, S.
• Application Number:
  US09/004,063
• Time in Patent Office: 656 Days
• Field of Search: 514/222.5, 514/422, 424/404, 424/400, 424/408, 424/409, 424/436
• US Class Current: 514/222.5
• CPC Class Codes: A61K 31/549 having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

A method and composition for treatment of a microbial infection of a patient involves introduction into the gut of a patient an antimicrobial amount of an antimicrobial medicament which is cell wall constituent-inactivating, endotoxin non-releasing, exotoxin-inactivating or a combination thereof.

Claims

1. A method of treating a microbial infection within a patient'"'"'s intestine, selected from the group consisting of an intestinal bacterial infection, an intestinal fungal infection and a combination thereof, comprising:

orally administering so as to introduce into a patient'"'"'s gut a non-antibiotic antimicrobial medicament which is microbial cell wall constituent-inactivating by cell wall cross-linking, endotoxin non-releasing, and/or exotoxin-inactivating, and combinations thereof, so as to treat said microbial intestinal infection of said patient.

2. The method of claim 1 wherein said antimicrobial medicament is administered in a tablet, capsule, liquid, suspension or suppository.

3. The method of claim 1 wherein said antimicrobial medicament is administered so that said medicament is continuously present in said gut over a course of the treatment.

4. The method of claim 1, further including intravenous administration in conjunction with the oral administration thereof.

5. The method of claim 1 wherein the microbial infection is by an antibiotic-resistant microorganism.

6. The method of claim 1 wherein the microbial infection is by a gram negative bacterium or a gram positive bacterium.

7. The method of claim 1 wherein the microbial infection is by Enterococci.

8. The method of claim 7 wherein the Enterococci are antibiotic-resistant Enterococci.

9. The method of claim 8 wherein the microbial infection is by vancomycin-resistant Enterococcus faecalis (VRE).

10. The method of claim 1 wherein the microbial infection is by Staphylococci.

11. The method of claim 10 wherein the Staphylococci are antibiotic-resistant.

12. The method of claim 11 wherein the microbial infection is by methicillin-resistant Staphylococcus aureus (MRSA).

13. The method of claim 1 wherein the microbial infection is by antibiotic-resistant Enterococcus faecium.

14. The method of claim 1 wherein the antimicrobial medicament is selected from the group consisting of taurolidine, taurultam and a combination thereof.

17. The method of claim 1 wherein the microbial intestinal infection causes diarrhea in the patient, and wherein said medicament is administered to said patient so as to treat said diarrhea.

15. A method of treating an intestinal bacterial infection, an intestinal fungal infection or a combination thereof within a patient'"'"'s intestine, absent infections due to surgery and injury, comprising orally administering so as to introduce into a patient'"'"'s gut a medicament comprising taurolidine, taurultam or a combination thereof, so as to treat said intestinal infection of said patient.

16. The method of claim 15 wherein said infection is an infection by vancomycin-resistant Enterococcus faecalis (VRE) or methicillin-resistant Staphylococcus aureus (MRSA).

18. The method of claim 15 wherein the microbial intestinal infection causes diarrhea in the patient, and wherein said medicament is administered to said patient so as to treat said diarrhea.